Idiopathic Pulmonary Fibrosis (IPF) is the most common type of PF, and its prevalence is on the rise globally. Numerous Phase 2 and Phase 2b/3 trials are underway for the development of new IPF treatments. ...
Our articles provide quick read summaries to help keep you informed and looking forward with industry insights.
Idiopathic Pulmonary Fibrosis (IPF) is the most common type of PF, and its prevalence is on the rise globally. Numerous Phase 2 and Phase 2b/3 trials are underway for the development of new IPF treatments. ...
Discover 4 reasons to partner with a clinical endpoint expert for your next respiratory trial....
Learn five facts about the current state of clinical trials including details about trial costs, enrollment issues, and the difficulty and complexity of today's studies....
Given that the relative survival rate of patients diagnosed with metastatic lung cancer is low, and that traditional chemotherapy and surgery are of limited efficacy, ADCs represent a potentially important treatment option....
MERIT’s most recent webinar provided an interactive Q & A style session discussing how early phase centralized image storage can help sponsors secure funding. ...
Our ophthalmology case studies illustrate how we seamlessly manage the imaging components of your trial, creating efficiencies for your drug development. ...
Tune into our webinars for subject matter expertise on a variety of key topics.
We enjoy meeting sponsors, partners, and industry professionals! Network with us at an upcoming conference.
Looking for real-world examples of how MERIT has supported sponsor clinical trial endpoints?
MERIT provided fast, accurate reads to support the quick turnaround times of a biotech's retrospective review of an early phase Glioma study. ...
MERIT was engaged mid-study to supply the high-quality imaging data and expertise needed to keep a Phase II glioblastoma study on track. Learn how this resulted in a significant cost savings for the Sponsor....
Anti-VEGF treatment via intravitreal injection has the potential to offer improved outcomes in the high-risk, vulnerable premature newborn population with ROP. Learn more in our case study. ...
Learn how high-quality retinal images were key to this pilot study’s success and formed the basis for testing an AI algorithm....
Our Solutions Guides provide an in-depth look at MERIT’s services, capabilities, and expertise.
Our Info Sheets are all downloadable and include helpful checklists, challenge and solution guides, and additional brief cheat sheets.
Looking for in-depth information on industry trends and how MERIT is helping sponsors and CROs address the challenges and opportunities of today’s market?
Learn about disease states, viral and non-viral vectors, routes of delivery, specialized endpoints, and future directions for gene therapy in the treatment of IRDs....
Learn how UWF imaging contributes to understanding pathology in the peripheral retina (particularly with diabetic retinopathy), about current UWF imaging systems, and potential future innovations....
In this white paper you will learn four potential issues presented in MBPCs and how you can solve for these with MERIT....
Featured news/media releases.
MERIT's EXCELSIOR imaging software has received expansion of its FDA 510(k) market clearance (K#220929). The expanded clearance includes new indications for use such as interpretation and evaluation of radiologic images (CT, MR and PET) in clinical trials....